participants see appendix.
The median compliance rate for patients not developing epithelial keratitis was 97% (25th and 75th quartiles of 50% and 139%) and for patients developing epithelial keratitis was 136% (25th and 75th quartiles of 114% and 150%). Adverse effects attributed to trifluridine solution were acute blepharitis (one patient), acute conjunctivitis (nine patients), and corneal epithelial erosions (11 patients) .
No statistically significant differences in the occurrence of HSV epithelial keratitis were found when comparing the study treatment groups ( Sundmacher' further showed that trifluridine solution five times daily reduced the occurrence of HSV epithelial keratitis from 21% in a placebo group to none in a trifluridine group during 4 months of treatment with topical dexamethasone. Vidarabine and acyclovir ointments are also effective in preventing HSV epithelial keratitis during corticosteroid therapy.78 The Herpetic Eye Disease Study (HEDS) designated trifluridine prophylaxis for all study patients with stromal keratitis or iridocyclitis and found that HSV epithelial keratitis recurred in 4.6% during 16 weeks of treatment and follow up.
Oral acyclovir is as effective as a topical antiviral in preventing recurrent epithelial disease during corticosteroid therapy of HSV stromal keratitis.8 Two HEDS trials evaluated the role of oral acyclovir in treating HSV stromal keratitis or iridocyclitis at a dosage providing therapeutic levels in the tear film9 and aqueous humour.'0 In evaluating the effect of oral Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis 
KERATITIS
It remains unclear why HSV epithelial keratitis recurs in some patients despite trifluridine prophylaxis during the treatment of HSV stromal keratitis or iritis. Because of the small number of episodes of epithelial recurrences observed in this study, the scope for statistical analysis of risk factors is limited. Furthermore, a bias towards underrecognition of epithelial keratitis could have occurred because patients with persistent or progressive stromal keratouveitis were not periodically evaluated for recurrent dendrites after they failed study medications. We therefore performed only univariate analyses, used survival analytic methods that included the exact time to onset of all recurrences, assumed the simplest possible parametric model for survival times, and provided sufficient information for future meta-analysis should additional data become available.
Despite potential limitations, our analysis suggests that patients with previous HSV epithelial keratitis have a higher rate of HSV epithelial keratitis during treatment of stromal keratitis or iritis and thus supports previous observations that patients with multiple past episodes of HSV keratitis tend to have future recurrences."2 We also noted that the dendrite often occurred at or near the location of recent stromal inflammation, an observation that could be due to shedding from the same corneal nerves, by increased susceptibility of damaged epithelium, or by reactivation of latent corneal virus. Our additional finding that non-white patients were more liable to develop an epithelial recurrence is difficult to explain. Whether certain people are more susceptible to recurrent ocular HSV infection needs to be further assessed.
Viral and host factors may play roles in recurrent episodes of HSV keratitis. Some patients may be predisposed to recurrent epithelial keratitis despite antiviral prophylaxis and may need to be followed more closely during treatment of HSV stromal keratouveitis.
